Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.47 |
| ▸ | PGR | P06401 | 4/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503304 | 1.00 | NR3C1 (0.47) | NR3C1PGRNR3C2AR | |
| SCHEMBL5502131 | 1.00 | NR3C1 (0.47) | NR3C1PGRNR3C2AR | |
| SCHEMBL5497425 | 0.80 | PGR (0.48) | NR3C1PGRNR3C2AR | |
| SCHEMBL5501221 | 0.76 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL5503482 | 0.76 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL5500107 | 0.76 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL5501223 | 0.76 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL5503488 | 0.76 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL5506638 | 0.73 | NR3C1 (0.44) | NR3C1PGRNR3C2AR | |
| SCHEMBL5506633 | 0.73 | NR3C1 (0.44) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | NR3C1 533/4885PGR 953/4885NR3C2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.